You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Guidelines & Advice

About Guidelines Email Guidelines Team

Cancer Continuum

Every stage in the cancer continuum requires different imaging, supportive care and other services. The guidelines provide evidence-based recommendations for care during each stage of the cancer continuum. The Cancer Continuum consists of the following stages:

Prevention Screening Diagnosis Treatment End-of-Life Survivorship Integrated Care

Displaying Guidelines

231 Items

Managing System Pressures for Sarcoma Service Delivery in Ontario

Document Status: Current
ID: GL-C50-05

Jan 2009

Minimal Residual Disease Testing in Acute Leukemia

Document Status: Current
ID: MOTAC-6
Version: 2

Sep 2020

Models of Care for Cancer Survivorship

Document Status: Current
ID: 26-1
Version: 2

Mar 2017

Multidisciplinary Cancer Conference Standards

Document Status: Current
ID: MCC

Jun 2006

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Document Status: Current
ID: GL 27-2
Version: 2

Feb 2021

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Document Status: Current
ID: GL 4-1
Version: 2

Jan 2021

Oncology Caregiver Support Framework

Document Status: Current
ID: N/A
Version: N/A

Oct 2019

Oncology Nursing Telepractice Standards

Document Status: Current
Version: N/A

Aug 2019

Ontario Cervical Screening Program: Guidance for Vaginal Vault Testing

Document Status: Current

Updated

Mar 2025

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Document Status: Current

Updated

Mar 2025

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Document Status: Current
ID: GL-END 3-25

Nov 2023

Ontario Oncology Information System Standards: Defining its Meaningful Use

Document Status: Current
ID: GL-C50-14

Mar 2014